196 related articles for article (PubMed ID: 31695341)
1. Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).
Ström T; Kozlovacki G; Myrenfors P; Almquist M
Patient Prefer Adherence; 2019; 13():1799-1807. PubMed ID: 31695341
[TBL] [Abstract][Full Text] [Related]
2. PRESTO 2: An International Survey to Evaluate Patients' Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly.
O'Toole D; Kunz PL; Webb SM; Goldstein G; Khawaja S; McDonnell M; Boiziau S; Gueguen D; Houchard A; Ribeiro-Oliveira A; Prebtani A
Adv Ther; 2023 Feb; 40(2):671-690. PubMed ID: 36502449
[TBL] [Abstract][Full Text] [Related]
3. An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).
Ferone D; Martin W; Williams J; Houchard A; Pommie C; Ribeiro-Oliveira A; Grossman AB
J Endocrinol Invest; 2024 Feb; 47(2):421-432. PubMed ID: 37550552
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
5. A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors.
Seo C; Horodniceanu E; Shah R; Goldstein G; Ray D; Bennett B; Phan A; McCarrier K
Support Care Cancer; 2022 Jul; 30(7):6307-6316. PubMed ID: 35476113
[TBL] [Abstract][Full Text] [Related]
6. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
[TBL] [Abstract][Full Text] [Related]
7. Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors.
Clarke CN; Cockrum P; Beveridge TJR; Jerry M; McMorrow D; Tran AT; Phan AT
J Health Econ Outcomes Res; 2023; 10(2):121-131. PubMed ID: 38093906
[No Abstract] [Full Text] [Related]
8. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO).
Adelman D; Truong Thanh XM; Feuilly M; Houchard A; Cella D
Adv Ther; 2020 Apr; 37(4):1608-1619. PubMed ID: 32157626
[TBL] [Abstract][Full Text] [Related]
10. Self-Administration of Long-Acting Somatostatin Analogues in NET Patients-Does It Affect the Clinical Outcome?
Sowa-Staszczak A; Opalińska M; Kurzyńska A; Morawiec-Sławek K; Gilis-Januszewska A; Palen-Tytko J; Olearska H; Hubalewska-Dydejczyk A
Medicina (Kaunas); 2021 Nov; 57(12):. PubMed ID: 34946232
[No Abstract] [Full Text] [Related]
11. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Saif MW; Fu J; Smith MH; Weinstein B; Relias V; Daly KP
J Pancreat Cancer; 2018; 4(1):64-71. PubMed ID: 30788459
[No Abstract] [Full Text] [Related]
12. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
[TBL] [Abstract][Full Text] [Related]
13. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study.
Adelman DT; Burgess A; Davies PR
Med Devices (Auckl); 2012; 5():103-9. PubMed ID: 23293542
[TBL] [Abstract][Full Text] [Related]
15. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
[TBL] [Abstract][Full Text] [Related]
16. Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.
Ayyagari R; Neary M; Li S; Rokito A; Yang H; Xie J; Benson AB
Am Health Drug Benefits; 2017 Nov; 10(8):408-415. PubMed ID: 29263774
[TBL] [Abstract][Full Text] [Related]
17. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
19. Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect.
Saif MW; Romano A; Smith MH; Patel R; Relias V
Cancer Med J; 2020; 3(2):75-84. PubMed ID: 32405630
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]